WO2015024042A1 - Immunoreceptor modulation for treating cancer and viral infections - Google Patents

Immunoreceptor modulation for treating cancer and viral infections Download PDF

Info

Publication number
WO2015024042A1
WO2015024042A1 PCT/AU2013/001132 AU2013001132W WO2015024042A1 WO 2015024042 A1 WO2015024042 A1 WO 2015024042A1 AU 2013001132 W AU2013001132 W AU 2013001132W WO 2015024042 A1 WO2015024042 A1 WO 2015024042A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
mammal
inhibitory agent
antibody
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2013/001132
Other languages
English (en)
French (fr)
Inventor
Mark Smythe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QIMR Berghofer Medical Research Institute
Original Assignee
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013903189A external-priority patent/AU2013903189A0/en
Application filed by Queensland Institute of Medical Research QIMR filed Critical Queensland Institute of Medical Research QIMR
Priority to JP2016535268A priority Critical patent/JP2016530267A/ja
Priority to MX2016002265A priority patent/MX2016002265A/es
Priority to US14/913,347 priority patent/US20160200814A1/en
Priority to KR1020167007431A priority patent/KR20160055818A/ko
Priority to CN201380079711.6A priority patent/CN105636983A/zh
Priority to CA2921772A priority patent/CA2921772A1/en
Priority to EP13891700.0A priority patent/EP3036255A4/en
Priority to BR112016003528A priority patent/BR112016003528A8/pt
Priority to AU2013398294A priority patent/AU2013398294A1/en
Priority to SG11201601285XA priority patent/SG11201601285XA/en
Priority to CA2921774A priority patent/CA2921774C/en
Priority to HUE14838641A priority patent/HUE063307T2/hu
Priority to MX2016002263A priority patent/MX2016002263A/es
Priority to AU2014308552A priority patent/AU2014308552B2/en
Priority to US14/913,348 priority patent/US20160208000A1/en
Priority to PL14838641.0T priority patent/PL3036258T3/pl
Priority to KR1020257003382A priority patent/KR20250024106A/ko
Priority to HRP20231186TT priority patent/HRP20231186T1/hr
Priority to EP14838641.0A priority patent/EP3036258B1/en
Priority to FIEP14838641.0T priority patent/FI3036258T3/fi
Priority to SG11201601283PA priority patent/SG11201601283PA/en
Priority to PCT/AU2014/000830 priority patent/WO2015024060A1/en
Priority to ES14838641T priority patent/ES2967538T3/es
Priority to MYPI2016000314A priority patent/MY192043A/en
Priority to BR112016003532A priority patent/BR112016003532A8/pt
Priority to HK16113673.9A priority patent/HK1225396A1/zh
Priority to SI201432042T priority patent/SI3036258T1/sl
Priority to NZ717534A priority patent/NZ717534A/en
Priority to JP2016535272A priority patent/JP6618908B2/ja
Priority to KR1020237018788A priority patent/KR20230085220A/ko
Priority to CN201480052069.7A priority patent/CN105636985A/zh
Priority to DK14838641.0T priority patent/DK3036258T3/da
Priority to KR1020167007435A priority patent/KR20160055819A/ko
Publication of WO2015024042A1 publication Critical patent/WO2015024042A1/en
Anticipated expiration legal-status Critical
Priority to JP2019205385A priority patent/JP2020059714A/ja
Priority to US16/938,214 priority patent/US20210047403A1/en
Priority to JP2022012145A priority patent/JP2022044808A/ja
Priority to JP2023134163A priority patent/JP2023156487A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Definitions

  • NK cells are innate lymphocytes critical to limit early tumor growth and metastasis NK cell functions are also regulated by the integration of signals transmitted by a wide range of activating and inhibitory receptors 2 .
  • activating receptors such as NCRs, NKG2D, or DNAM-1 stimulate NK cells cytotoxicity and the secretion of pro-inflammatory mediators such as interferon gamma (IFN-y) 3 .
  • IFN-y interferon gamma
  • inhibitory receptors protect target cells from NK cell- ⁇
  • CD96 acts as a negative regulator of T cell and NK cell anti-tumor functions. Accordingly, the invention is broadly directed to use of agents that at least partly block or inhibit CD96 to thereby reduce or relieve CD96-mediated immune inhibition to enhance or restore immune surveillance in the mammal. In certain embodiments, this may facilitate treatment of diseases or conditions responsive at least partial blocking or inhibition of CD96, such as cancers and/or viral infections.
  • the CD96-inhibitory agent is an anti- viral agent.
  • FIG. 1 CD96 competes with DNAM-1 for CD155 binding
  • a, b The expression of CD96 was analyzed by flow cytometry on the indicated spleen lymphocyte populations from C57BL/6 WT (light grey) and CD96 J - mice (dark grey). The representative FACS Histograms (a) and the mean + SD (b) of 3 mice from one representative experiment out of 3 are shown, c, d
  • the expression of CD96, DNAM- 1 and TIGIT was determined on WT spleen NK cells freshly isolated or activated for 48 hrs with IL-2 (1000 U/ml). e.
  • CD96 and TIGIT compete with DNAM-1 for the binding of CD155 at the cell surface of B16F10.
  • the binding of DNAM-1 -Fc labeled with AF-647 (0.5-20 ⁇ g ml) at the cell surface of B16F10 cells was analyzed in the presence of 50 g ml of control Ig, recombinant CD96 or TIGIT-Fc.
  • the FACS histograms and the mean + SD of triplicate wells from one representative experiment out of 3 are shown, d.
  • a 4 hr 5l Cr release assay was performed between B16F10 cells and IL-2-activated NK cells from WT, DNAM-1 1' and CD9G 1' mice at the indicated effector target ratios.
  • the elements of the immune system are one or more cells that normally express CD96, such as T cells, inclusive of CD4 + and CD8 + T cells ⁇ cells, NKT cells and natural killer (NK) cells.
  • administering is meant the introduction of the CD96-inhibitory agent into the mammal by a particular route.
  • a therapeutically effective amount of the CD96-inhibitory agent is administered to the mammal.
  • the method of the invention may be useful in reducing or relieving CD96-mediated immune inhibition, suppression or peripheral tolerance.
  • the method facilitates treatment or prevention of one or more diseases or conditions that are responsive to at least partly blocking CD96-mediated immune inhibition, suppression or peripheral tolerance.
  • the one or more other agents that facilitate cancer treatment or prevention may be administered in combination with the CD96-inhibitory agent or be administered separately, as is well understood in the art.
  • pharmaceutically-acceptable carrier diluent or excipient
  • a solid or liquid filler diluent or encapsulating substance that may be safely used in systemic administration.
  • carriers, diluents and excipients well known in the art may be used. These carriers, diluents and excipients may be selected from a group including sugars, f
  • the CD96 deletion was backcrossed onto a C57BL/6 background, facilitated by a genome- wide screening of polymorphic microsatellite markers at 10- centiMorgan intervals at each generation.
  • CD96 +/" >99% C57BL/6 mice were intercrossed to generate the CD96 ⁇ _ mice.
  • DNAM-1 "A mice have already been described.
  • DNAM-1 A CD96 'A were generated by intercrossing CD96 '7" with DNAM- Y 1' mice. Mice were bred and used between the ages of 6-14 weeks. All experiments were approved by animal ethics committee.
  • mice were checked hourly for symptoms of sepsis. Serum from these mice was taken at various time points by retro-orbital or cardiac bleeding for cytokine analysis. Spleens were Jt"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PCT/AU2013/001132 2013-08-22 2013-10-03 Immunoreceptor modulation for treating cancer and viral infections Ceased WO2015024042A1 (en)

Priority Applications (37)

Application Number Priority Date Filing Date Title
JP2016535268A JP2016530267A (ja) 2013-08-22 2013-10-03 癌及びウイルス感染症を治療するための免疫受容体調節
MX2016002265A MX2016002265A (es) 2013-08-22 2013-10-03 Modulacion de inmunoreceptor para tratar cancer e infecciones virales.
US14/913,347 US20160200814A1 (en) 2013-08-22 2013-10-03 Immunoreceptor modulation for treating cancer and viral infections
KR1020167007431A KR20160055818A (ko) 2013-08-22 2013-10-03 암 및 바이러스 감염을 치료하기 위한 면역수용체 조절
CN201380079711.6A CN105636983A (zh) 2013-08-22 2013-10-03 用于治疗癌症和病毒感染的免疫受体调节
CA2921772A CA2921772A1 (en) 2013-08-22 2013-10-03 Immunoreceptor modulation for treating cancer and viral infections
EP13891700.0A EP3036255A4 (en) 2013-08-22 2013-10-03 Immunoreceptor modulation for treating cancer and viral infections
BR112016003528A BR112016003528A8 (pt) 2013-08-22 2013-10-03 modulação de receptor imuno para tratamento de câncer e infecções virais
AU2013398294A AU2013398294A1 (en) 2013-08-22 2013-10-03 Immunoreceptor modulation for treating cancer and viral infections
SG11201601285XA SG11201601285XA (en) 2013-08-22 2013-10-03 Immunoreceptor modulation for treating cancer and viral infections
KR1020167007435A KR20160055819A (ko) 2013-08-22 2014-08-22 암 및 바이러스 감염을 치료하기 위한 면역수용체 조절
EP14838641.0A EP3036258B1 (en) 2013-08-22 2014-08-22 Immunoreceptor modulation for treating cancer and viral infections
HK16113673.9A HK1225396A1 (zh) 2013-08-22 2014-08-22 用於治疗癌症和病毒感染的免疫受体调节
MX2016002263A MX2016002263A (es) 2013-08-22 2014-08-22 Modulacion de inmunoreceptor para tratar cancer e infecciones virales.
AU2014308552A AU2014308552B2 (en) 2013-08-22 2014-08-22 Immunoreceptor modulation for treating cancer and viral infections
US14/913,348 US20160208000A1 (en) 2013-08-22 2014-08-22 Immunoreceptor modulation for treating cancer and viral infections
PL14838641.0T PL3036258T3 (pl) 2013-08-22 2014-08-22 Modulowanie receptora dla leczenia raka i infekcji wirusowych
KR1020257003382A KR20250024106A (ko) 2013-08-22 2014-08-22 암 및 바이러스 감염을 치료하기 위한 면역수용체 조절
HRP20231186TT HRP20231186T1 (hr) 2013-08-22 2014-08-22 Modulacija imunoreceptora za liječenje raka i virusnih infekcija
CA2921774A CA2921774C (en) 2013-08-22 2014-08-22 Immunoreceptor modulation for treating cancer and viral infections
FIEP14838641.0T FI3036258T3 (fi) 2013-08-22 2014-08-22 Immunoreseptorin modulointi syövän ja virusinfektioiden hoitamiseksi
SG11201601283PA SG11201601283PA (en) 2013-08-22 2014-08-22 Immunoreceptor modulation for treating cancer and viral infections
PCT/AU2014/000830 WO2015024060A1 (en) 2013-08-22 2014-08-22 Immunoreceptor modulation for treating cancer and viral infections
ES14838641T ES2967538T3 (es) 2013-08-22 2014-08-22 Modulación del inmunorreceptor para el tratamiento del cáncer e infecciones virales
MYPI2016000314A MY192043A (en) 2013-08-22 2014-08-22 Immunoreceptor modulation for treating cancer and viral infections
BR112016003532A BR112016003532A8 (pt) 2013-08-22 2014-08-22 modulação imunorreceptora para tratar o cancer e as infecções virais
HUE14838641A HUE063307T2 (hu) 2013-08-22 2014-08-22 Rák és vírusfertõzések kezelésére szolgáló immunreceptor-moduláció
SI201432042T SI3036258T1 (sl) 2013-08-22 2014-08-22 Modulacija imunoreceptorjev za zdravljenje raka in virusnih infekcij
NZ717534A NZ717534A (en) 2013-08-22 2014-08-22 Immunoreceptor modulation for treating cancer and viral infections
JP2016535272A JP6618908B2 (ja) 2013-08-22 2014-08-22 免疫抑制を低減又は軽減するためのｃｄ９６阻害抗体又は抗体断片の使用
KR1020237018788A KR20230085220A (ko) 2013-08-22 2014-08-22 암 및 바이러스 감염을 치료하기 위한 면역수용체 조절
CN201480052069.7A CN105636985A (zh) 2013-08-22 2014-08-22 用于治疗癌症和病毒感染的免疫受体调节
DK14838641.0T DK3036258T3 (da) 2013-08-22 2014-08-22 Immunreceptormodulering til behandling af cancer og virusinfektioner
JP2019205385A JP2020059714A (ja) 2013-08-22 2019-11-13 癌及びウイルス感染症を治療するための免疫受容体調節
US16/938,214 US20210047403A1 (en) 2013-08-22 2020-07-24 Immunoreceptor modulation for treating cancer and viral infections
JP2022012145A JP2022044808A (ja) 2013-08-22 2022-01-28 癌及びウイルス感染症を治療するための免疫受容体調節
JP2023134163A JP2023156487A (ja) 2013-08-22 2023-08-21 癌及びウイルス感染症を治療するための免疫受容体調節

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2013903189A AU2013903189A0 (en) 2013-08-22 Immunomodulator
AU2013903189 2013-08-22

Publications (1)

Publication Number Publication Date
WO2015024042A1 true WO2015024042A1 (en) 2015-02-26

Family

ID=52482821

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2013/001132 Ceased WO2015024042A1 (en) 2013-08-22 2013-10-03 Immunoreceptor modulation for treating cancer and viral infections

Country Status (12)

Country Link
US (1) US20160200814A1 (enExample)
EP (1) EP3036255A4 (enExample)
JP (1) JP2016530267A (enExample)
KR (1) KR20160055818A (enExample)
CN (1) CN105636983A (enExample)
AU (1) AU2013398294A1 (enExample)
BR (1) BR112016003528A8 (enExample)
CA (1) CA2921772A1 (enExample)
HK (1) HK1225395A1 (enExample)
MX (1) MX2016002265A (enExample)
SG (1) SG11201601285XA (enExample)
WO (1) WO2015024042A1 (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US9512227B2 (en) 2014-03-12 2016-12-06 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease
WO2017220990A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
WO2019030377A1 (en) * 2017-08-11 2019-02-14 Blink Biomedical Sas CD96 BINDING AGENTS AS IMMUNOMODULATORS
US10344090B2 (en) 2013-12-12 2019-07-09 Shanghai Hangrui Pharmaceutical Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
WO2020132034A1 (en) 2018-12-20 2020-06-25 23Andme, Inc. Anti-cd96 antibodies and methods of use thereof
EP3565889A4 (en) * 2017-01-06 2020-12-16 Nantkwest, Inc. CD96 / TIGIT GENETICALLY MODIFIED REDUCED EXPRESSION NK-92 CELLS
US10995141B2 (en) 2019-04-19 2021-05-04 ImmunoBrain Checkpoint, Inc. Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease
EP4052727A4 (en) * 2019-10-30 2023-12-20 University of Tsukuba IMMUNE RESPONSE INHIBITOR

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10144779B2 (en) 2015-05-29 2018-12-04 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
MA50949B1 (fr) 2016-12-07 2023-12-29 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et leurs procédés d'utilisation
TWI758558B (zh) 2017-11-10 2022-03-21 大陸商江蘇恒瑞醫藥股份有限公司 Cd96抗體、其抗原結合片段及醫藥用途
BR112022005787A2 (pt) * 2019-09-27 2022-06-21 Glaxosmithkline Ip Dev Ltd Proteínas de ligação a antígeno
CN116377061B (zh) * 2022-11-28 2024-01-16 中山大学孙逸仙纪念医院 乳腺癌新辅助化疗耐药标志物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073316A2 (en) * 2006-12-07 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Identification and isolation of acute myeloid leukemia stem cells
WO2009126688A2 (en) * 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
WO2011057216A1 (en) * 2009-11-06 2011-05-12 The Pennsylvania State Research Foundation Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1777622A (zh) * 2003-02-24 2006-05-24 施里昂药品股份公司 脊髓灰质炎病毒受体功能的调节
EP1481993A1 (en) * 2003-05-28 2004-12-01 Xerion Pharmaceuticals AG Modulation of the poliovirus receptor function
WO2005107799A1 (ja) * 2004-05-06 2005-11-17 Eisai R & D Management Co., Ltd. 抗Necl-5抗体を有効成分として含む癌治療剤
CN102204901A (zh) * 2010-03-30 2011-10-05 中国科学院上海生命科学研究院 调节免疫分子的试剂和方法
NZ717534A (en) * 2013-08-22 2022-04-29 Council Queensland Inst Medical Res Immunoreceptor modulation for treating cancer and viral infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073316A2 (en) * 2006-12-07 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Identification and isolation of acute myeloid leukemia stem cells
WO2009126688A2 (en) * 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
WO2011057216A1 (en) * 2009-11-06 2011-05-12 The Pennsylvania State Research Foundation Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BARTH, B.M. ET AL.: "Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia.", ACS NANO., vol. 5, no. 7, 26 July 2011 (2011-07-26), pages 5325 - 37, XP055284785 *
CHAN, C.J.: "Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer.", CURR OPIN IMMUNOL., vol. 24, no. 2, April 2012 (2012-04-01), pages 246 - 51, XP055147483 *
FUCHS, A ET AL.: "The role of NK cell recognition of nectin and nectin-lik proteins in tumor immunosurveillance.", SEMIN CANCER BIOL., vol. 16, no. 5, October 2006 (2006-10-01), pages 359 - 66, XP024908054 *
FUCHS, A. ET AL.: "Cutting edge: CD 96 (tactile) promotes NK cell -target cell adhesion by interacting with the poliovirus receptor ( CD 155).", J IMMUNOL., vol. 172, no. 7, 1 April 2004 (2004-04-01), pages 3994 - 8, XP055284790 *
GONG, J. ET AL.: "Establishment of an enzyme-linked immunosorbent assay system for determining soluble CD 96 and its application in the measurement of sCD96 in patients with viral hepatitis B and hepatic cirrhosis.", CLIN EXP IMMUNOL., vol. 155, no. 2, February 2009 (2009-02-01), pages 207 - 15, XP055284787 *
GRAMATZKI, M. ET AL.: "Antibodies TC-12 (''unique'') and TH -111 ( CD 96) characterize T- cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia.", EXP HEMATOL., vol. 26, no. 13, December 1998 (1998-12-01), pages 1209 - 14, XP008109027 *
LARSEN, H. ET AL.: "Nonviral transfection of leukemic primary cells and cells lines by siRNA-a direct comparison between Nucleofection and Accell delivery.", EXP HEMATOL., vol. 39, no. 11, November 2011 (2011-11-01), pages 1081 - 9, XP028318425 *
MOHSENI NODEHI, S. ET AL.: "Enhanced ADCC activity of affinity maturated and Fc- engineered mini-antibodies directed against the AML stem cell antigen CD 96.", PLOS ONE., vol. 7, no. 8, 2012, pages E42426., XP055284783 *
See also references of EP3036255A4 *
SETH, S. ET AL.: "The murine pan T cell marker CD 96 is an adhesion receptor for CD 155 and nectin-1.", BIOCHEM BIOPHYS RES COMMUN., vol. 364, no. 4, 28 December 2007 (2007-12-28), pages 959 - 65, XP022344218 *
STANIETSKY, N ET AL.: "Paired NK cell receptors controlling NK cytotoxicity.", FEBS LETT., vol. 584, no. 24, 15 December 2010 (2010-12-15), pages 4895 - 900, XP055284792 *
ZENG, J.M. ET AL.: "Human CD 96 gene cloning, expression and identification''.", NAN FANG YI KE DA XUE XUE BAO., vol. 31, no. 7, June 2011 (2011-06-01), pages 1232 - 5 *

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10344090B2 (en) 2013-12-12 2019-07-09 Shanghai Hangrui Pharmaceutical Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
US11365255B2 (en) 2013-12-12 2022-06-21 Suzhou Suncadia Biopharmaceuticals Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
US9982051B2 (en) 2014-03-12 2018-05-29 Yeda Research And Development Co. Ltd. Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10214585B2 (en) 2014-03-12 2019-02-26 Yeda Research And Development Co., Ltd. Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US11884728B2 (en) 2014-03-12 2024-01-30 Yeda Research And Development Co. Ltd. Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis
US11492405B2 (en) 2014-03-12 2022-11-08 Yeda Research And Development Co. Ltd Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the CNS
US9512227B2 (en) 2014-03-12 2016-12-06 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease
US9856318B2 (en) 2014-03-12 2018-01-02 Yeda Research And Development Co., Ltd. Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US9982050B2 (en) 2014-03-12 2018-05-29 Yeda Research And Development Co. Ltd. Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9982049B2 (en) 2014-03-12 2018-05-29 Yeda Research And Development Co. Ltd. Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US9982048B2 (en) 2014-03-12 2018-05-29 Yeda Research And Development Co. Ltd. Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease
US10144778B2 (en) 2014-03-12 2018-12-04 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US11884727B2 (en) 2014-03-12 2024-01-30 Yeda Research And Development Co. Ltd. Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis
US11643464B2 (en) 2014-03-12 2023-05-09 Yeda Research and Develpment & Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of a retinal degeneration disorder
US9534052B2 (en) 2014-03-12 2017-01-03 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease
US9512225B2 (en) 2014-03-12 2016-12-06 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease
US9982047B2 (en) 2014-03-12 2018-05-29 Yeda Research And Development Co. Ltd. Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10981989B2 (en) 2014-03-12 2021-04-20 Yeda Research And Development Co. Ltd. Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10961309B2 (en) 2014-03-12 2021-03-30 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
WO2017220990A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
EP3565889A4 (en) * 2017-01-06 2020-12-16 Nantkwest, Inc. CD96 / TIGIT GENETICALLY MODIFIED REDUCED EXPRESSION NK-92 CELLS
CN111655286A (zh) * 2017-08-11 2020-09-11 布林克生物医学简易股份公司 作为免疫调节剂的cd96结合剂
WO2019030377A1 (en) * 2017-08-11 2019-02-14 Blink Biomedical Sas CD96 BINDING AGENTS AS IMMUNOMODULATORS
WO2020132034A1 (en) 2018-12-20 2020-06-25 23Andme, Inc. Anti-cd96 antibodies and methods of use thereof
US11555073B2 (en) 2018-12-20 2023-01-17 23Andme, Inc. Anti-CD96 antibodies and methods of use thereof
US12365732B2 (en) 2018-12-20 2025-07-22 23Andme, Inc. Anti-CD96 antibodies and methods of use thereof
US11732046B2 (en) 2019-04-19 2023-08-22 ImmunoBrain Checkpoint, Inc. Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease
US10995141B2 (en) 2019-04-19 2021-05-04 ImmunoBrain Checkpoint, Inc. Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease
EP4052727A4 (en) * 2019-10-30 2023-12-20 University of Tsukuba IMMUNE RESPONSE INHIBITOR

Also Published As

Publication number Publication date
EP3036255A1 (en) 2016-06-29
SG11201601285XA (en) 2016-03-30
HK1225395A1 (zh) 2017-09-08
BR112016003528A8 (pt) 2018-01-30
CA2921772A1 (en) 2015-02-26
US20160200814A1 (en) 2016-07-14
EP3036255A4 (en) 2017-03-22
JP2016530267A (ja) 2016-09-29
KR20160055818A (ko) 2016-05-18
MX2016002265A (es) 2016-12-16
CN105636983A (zh) 2016-06-01
AU2013398294A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
US20210047403A1 (en) Immunoreceptor modulation for treating cancer and viral infections
US20160200814A1 (en) Immunoreceptor modulation for treating cancer and viral infections
JP7259107B2 (ja) Ｐｄ－１アゴニスト抗体およびその使用
JP6923714B2 (ja) Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体
US10302653B2 (en) Distinguishing antagonistic and agonistic anti B7-H1 antibodies
JP2022505679A (ja) Ｎｙ－ｅｓｏ－１ ｔ細胞受容体およびそれらの使用の方法
US11667709B2 (en) Anti-TIGIT antibodies and methods of use
Kubagawa et al. Authentic IgM Fc receptor (FcμR)
AU2014308552B2 (en) Immunoreceptor modulation for treating cancer and viral infections
US12195545B2 (en) Anti-OX40 monoclonal antibody and application thereof
Yu et al. Progranulin facilitates the increase of platelet count in immune thrombocytopenia
Saha Targeting the TIGIT/CD226/CD96 signaling Axis using the IgV domain of PVR
WO2025220689A1 (ja) Ｔ細胞機能不全のｔ細胞性腫瘍患者に有効な二重特異性抗体
BRPI0616438A2 (pt) proteÍna, polinucleotÍdeo, anticorpo contra uma proteÍna secretora ou de membrana, ou um fragmento funcional do mesmo, hibridoma, agente terapÊutico para uma doenÇa autoimune, agente para inibir adesço de cÉlulas t, e, mÉtodo para triar uma substÂncia
KR20250113410A (ko) 자가면역 장애에 대한 환자 선택 및 치료 모니터링
WO2020080298A1 (ja) 樹状細胞の成熟抑制剤及び成熟抑制方法、並びに医薬組成物
Radjabova et al. TARM1 is a novel LRC-encoded ITAM receptor that co-stimulates pro-inflammatory cytokine secretion by macrophages and neutrophils
Nakamura et al. Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13891700

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2921772

Country of ref document: CA

Ref document number: 2016535268

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14913347

Country of ref document: US

Ref document number: MX/A/2016/002265

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016003528

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: IDP00201601603

Country of ref document: ID

ENP Entry into the national phase

Ref document number: 2013398294

Country of ref document: AU

Date of ref document: 20131003

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20167007431

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013891700

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112016003528

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160219